Original Article
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
N Engl J Med 2004; 350:886-895February 26, 2004
- Abstract
Background
The prevalence of pulmonary hypertension in adults with sickle cell disease, the mechanism of its development, and its prospective prognostic significance are unknown.
Methods
We performed Doppler echocardiographic assessments of pulmonary-artery systolic pressure in 195 consecutive patients (82 men and 113 women; mean [±SD] age, 36±12 years). Pulmonary hypertension was prospectively defined as a tricuspid regurgitant jet velocity of at least 2.5 m per second. Patients were followed for a mean of 18 months, and data were censored at the time of death or loss to follow-up.
Results
Doppler-defined pulmonary hypertension occurred in 32 percent of patients. Multiple logistic-regression analysis, with the use of the dichotomous variable of a tricuspid regurgitant jet velocity of less than 2.5 m per second or 2.5 m per second or more, identified a self-reported history of cardiovascular or renal complications, increased systolic blood pressure, high lactate dehydrogenase levels (a marker of hemolysis), high levels of alkaline phosphatase, and low transferrin levels as significant independent correlates of pulmonary hypertension. The fetal hemoglobin level, white-cell count, and platelet count and the use of hydroxyurea therapy were unrelated to pulmonary hypertension. A tricuspid regurgitant jet velocity of at least 2.5 m per second, as compared with a velocity of less than 2.5 m per second, was strongly associated with an increased risk of death (rate ratio, 10.1; 95 percent confidence interval, 2.2 to 47.0; P<0.001) and remained so after adjustment for other possible risk factors in a proportional-hazards regression model.
Conclusions
Pulmonary hypertension, diagnosed by Doppler echocardiography, is common in adults with sickle cell disease. It appears to be a complication of chronic hemolysis, is resistant to hydroxyurea therapy, and confers a high risk of death. Therapeutic trials targeting this population of patients are indicated.
Media in This Article
Figure 1
Distribution (Panel A) and Frequency Distribution (Panel B) of Tricuspid Regurgitant Jet Velocity in 195 Patients with Sickle Cell Disease and 41 Black Control Subjects and the Association between Right Ventricular Systolic Pressure Measured by Doppler Echocardiography and Pulmonary-Artery Systolic Pressure, Measured during Catheterization (Panel C).Figure 2
Kaplan–Meier Survival Curves According to the Tricuspid Regurgitant Jet Velocity.Article Activity
- Article
Pulmonary hypertension develops in most forms of hereditary and chronic hemolytic anemia, including sickle cell disease,1 thalassemia,2 hereditary spherocytosis,3 and paroxysmal nocturnal hemoglobinuria,4 suggesting that there is a clinical syndrome of hemolysis-associated pulmonary hypertension. This complication has been reported with increasing frequency in patients with sickle cell disease.1,5-11 Retrospective studies from tertiary care referral centers suggest a prevalence of pulmonary hypertension ranging from 20 to 40 percent.9,11,12 Although these studies have demonstrated that patients with sickle cell disease have lower pulmonary pressures and higher cardiac output than patients with primary pulmonary hypertension, the two-year mortality rates approach 50 percent in both groups.6,10,11,13 The frequent reports of sudden death in adults with sickle cell disease in the absence of coronary artery disease and the high risk of sudden death in patients with sickle cell disease and pulmonary hypertension may be related.5,6,14,15 Such a relation would suggest that pulmonary hypertension may be a major cause of death in patients with sickle cell disease.
Methods
Patients
To avoid tertiary care referral bias, we recruited 195 patients from the community through multimedia advertisements, community outreach, and regional clinics. All evaluated patients were screened by means of history taking and physical examination, laboratory studies, and transthoracic echocardiography. All patients provided written informed consent. The advertisements and protocol were approved by the institutional review boards of the National Heart, Lung, and Blood Institute and Howard University.
Patients with sickle cell hemoglobinopathy documented by high-pressure liquid chromatography were eligible for the study. Only outpatients in stable condition were included; patients who had had a vaso-occlusive crisis within the previous two weeks or an episode of acute chest syndrome within the previous four weeks were evaluated at a later time. Patients receiving transfusions were not excluded. In addition, 41 black control subjects, with age and sex distributions similar to those of the patients, were evaluated for race-based comparisons of laboratory and echocardiographic data.
Echocardiography
Transthoracic echocardiography was performed in all patients with the use of the Acuson Sequoia (Siemens) and Sonos 5500 (Philips) systems. Cardiac measurements were performed according to the guidelines of the American Society of Echocardiography.16 Transmitral flow, Doppler determinations of the severity of valvular regurgitation, and left ventricular stroke volume were assessed and graded as previously described.17-19 Peak velocities of the E wave and A wave, the ratio of the E wave to the A wave, and the deceleration time were measured in a standard manner.20 Isovolumic relaxation time was measured as the time from aortic-valve closure to the start of mitral inflow.
Tricuspid regurgitation was assessed in the parasternal right ventricular inflow, parasternal short-axis, and apical four-chamber views, and a minimum of five sequential complexes were recorded. Continuous-wave Doppler sampling of the peak regurgitant jet velocity was used to estimate the right-ventricular-to-right-atrial systolic pressure gradient with the use of the modified Bernoulli equation (4 × [tricuspid regurgitant jet velocity]2).21 For the purpose of analysis, we prospectively defined pulmonary hypertension as a peak tricuspid regurgitant jet velocity of at least 2.5 m per second. Since most patients with clinically significant pulmonary hypertension have measurable tricuspid regurgitation,21 we assumed that pulmonary-artery pressures were normal in patients with trace or no tricuspid regurgitation.
Pulmonary-artery systolic pressure was quantitated by adding the Bernoulli-derived pressure gradient to the estimated mean right atrial pressure. The mean right atrial pressure was calculated according to the degree of collapse of the inferior vena cava with inspiration: 5 mm Hg for a collapse of at least 50 percent and 15 mm Hg for a collapse of less than 50 percent.22
Right Heart Catheterization
Right heart catheterizations were performed in 18 consenting patients with a tricuspid regurgitant jet velocity of at least 2.5 m per second.
Statistical Analysis
When tricuspid regurgitant jet velocity was analyzed as a continuous variable, undetectable values were assigned a value lower than any actually measured (1.3 m per second).21 We used t-tests and Wilcoxon rank-sum tests to compare continuous variables between patients with sickle cell disease and control subjects and the normal-approximation test to compare dichotomous variables, with no correction for continuity. For patients with sickle cell disease, associations between tricuspid regurgitant jet velocity and continuous variables were assessed by separate linear regression of each variable on tricuspid regurgitant jet velocity, defined as a categorical variable: 0 for values of less than 2.5 m per second, 1 for values of 2.5 to 2.9 m per second, and 2 for values of at least 3.0 m per second. Associations with dichotomous variables were assessed by means of the Armitage chi-square statistic for trend.
We used logistic-regression analysis of low values for tricuspid regurgitant jet velocity (less than 2.5 m per second) and high values (2.5 m per second or more) to obtain a set of variables that were independently associated with increasing jet velocity. Using both forward and backward selection methods in a stepwise procedure, we derived a model in which all variables had a calculated P value of less than 0.05 when they were added to the other variables in the model. We used proportional-hazards regression to assess variables that could be associated with an increased risk of death in patients with sickle cell disease. All regression analyses were performed with the use of log-transformed values (on a base 10 scale) for laboratory measurements in order to reduce the influence of extremely high values. Calculations were made with the use of Number Cruncher Statistical Systems software.
Results
Clinical Characteristics
The base-line characteristics of all 195 patients who were evaluated and the 41 black control subjects are shown in Table 1Table 1
Characteristics of the Patients with Sickle Cell Disease and Control Subjects.. The information for the patients is further categorized according to the values for tricuspid regurgitant jet velocity (less than 2.5 m per second, 2.5 to 2.9 m per second, and 3.0 m per second or more) in Table 2Table 2
Characteristics of Patients with Sickle Cell Disease According to the Tricuspid Regurgitant Jet Velocity.. The genotype on the basis of hematologic and hemoglobin characteristics was hemoglobin SS in 132 patients (69 percent), hemoglobin SC in 35 (18 percent), and hemoglobin S–thalassemia (β0 or β+) in 23 (12 percent). Data on genotype were missing for five patients.Prevalence and Severity of Pulmonary Hypertension
Values for pulmonary-artery systolic pressure as estimated by Doppler echocardiography accurately predicted pulmonary-artery systolic pressures measured during right heart catheterization (25 catheterizations performed in 18 patients) (r=0.77, P<0.001) (Figure 1CFigure 1
Distribution (Panel A) and Frequency Distribution (Panel B) of Tricuspid Regurgitant Jet Velocity in 195 Patients with Sickle Cell Disease and 41 Black Control Subjects and the Association between Right Ventricular Systolic Pressure Measured by Doppler Echocardiography and Pulmonary-Artery Systolic Pressure, Measured during Catheterization (Panel C).). The patients with sickle cell disease had significantly higher mean values for tricuspid regurgitant jet velocity than did the controls (P=0.003) (Figure 1A and Figure 1B and Table 1). Thirty-two percent of patients with sickle cell disease had elevated pulmonary-artery systolic pressures, as defined by a tricuspid regurgitant jet velocity of at least 2.5 m per second (an estimated pulmonary-artery systolic pressure of at least 30 mm Hg). Nine percent had pulmonary hypertension with the use of the more conservative cutoff value for tricuspid regurgitant jet velocity of at least 3.0 m per second (an estimated pulmonary-artery systolic pressure of at least 41 mm Hg) (Figure 1A). Of the 18 patients with a tricuspid regurgitant jet velocity of at least 2.5 m per second who underwent right heart catheterization, 17 had a mean pulmonary-artery pressure of more than 25 mm Hg (the definition of pulmonary hypertension used in the National Institutes of Health registry23).Effect of Pulmonary Hypertension on Ventricular Size and Function
Higher values for tricuspid regurgitant jet velocity were associated with increased cardiac-chamber sizes (Table 2). There was a slight decrease in the ejection fraction at the highest levels of jet velocity (P=0.10). There was no association between jet velocity and stroke volume, and cardiac output increased slightly but not significantly with increasing jet velocity (P=0.24). There was qualitative evidence of left ventricular systolic dysfunction (an ejection fraction of 0.5 or less) in only 5 of the 195 patients.
Measurements of the left ventricular diastolic function are shown in Table 2. Only the deceleration time was weakly associated with tricuspid regurgitant jet velocity (r=0.17, P=0.01), but the mean values remained in the normal range for all categories of tricuspid regurgitant jet velocity. Variables indicative of diastolic dysfunction did not contribute significantly to the logistic-regression model (Table 3Table 3
Logistic-Regression Analysis of a Tricuspid Regurgitant Jet Velocity Dichotomized as Less Than 2.5 m per Second or 2.5 m per Second or More.) or affect the risk of death, suggesting that pulmonary hypertension is largely independent of diastolic dysfunction.Evaluation of Risk Factors and Effects of Hydroxyurea Therapy
Logistic-regression analysis of clinical and laboratory values identified a number of factors associated with high tricuspid regurgitant jet velocity; these factors, which accounted for approximately 35 percent of the variability in tricuspid regurgitant jet velocity (Table 3), include a self-reported history of renal or cardiovascular problems; elevated systolic blood pressure, plasma lactate dehydrogenase levels, and alkaline phosphatase levels; and decreased plasma transferrin levels. In a model that included only men, priapism was an additional important variable (odds ratio for a jet velocity of at least 2.5 m per second, as compared with a value of less than 2.5 m per second, 5.0; 95 percent confidence interval, 1.5 to 17.0). Factors reflecting the presence of hemolysis, chronic anemia, and the need for frequent blood transfusions, including low hemoglobin and hematocrit values, high lactate dehydrogenase and aspartate aminotransferase levels (but not high alanine aminotransferase levels, which are specific to liver dysfunction), high direct bilirubin levels, high iron and ferritin levels, low transferrin levels, and the receipt of a total of more than 10 transfusions, were all significant univariate predictors of a high tricuspid regurgitant jet velocity (Table 2).
Increasing age, oxyhemoglobin desaturation as measured by pulse oximetry, and increasing levels of blood urea nitrogen, creatinine, and direct bilirubin were significant univariate — but not multivariate — predictors of high tricuspid regurgitant jet velocity. The plasma arginine:ornithine ratio, probably reflecting arginase activity, was low in patients with sickle cell disease, and this ratio decreased significantly as tricuspid regurgitant jet velocity increased. The fetal hemoglobin level, the hemoglobin S–thalassemia phenotype (β0 or β+), hydroxyurea therapy, the white-cell count, and the platelet count were not significantly associated with tricuspid regurgitant jet velocity, whereas the hemoglobin SC genotype was associated with a significantly reduced tricuspid regurgitant jet velocity (P=0.02 as calculated with the use of a t-test in which tricuspid regurgitant jet velocity was considered to be a continuous variable). Analysis of the patients who did not receive hydroxyurea or have hemoglobin C, as well as of all patients, showed no evidence of an association between the fetal hemoglobin level and tricuspid regurgitant jet velocity.
The number of episodes of the acute chest syndrome and the number of visits to the emergency room per year were not associated with tricuspid regurgitant jet velocity (P=0.92 and P=0.68, respectively). The fact that there were significantly more patients with a self-reported history of cardiovascular problems who had pulmonary hypertension suggests that pulmonary hypertension and its complications, such as cor pulmonale, may be misdiagnosed as congestive heart failure.
Right Heart Catheterization
Among the 18 patients who underwent right heart catheterization, the mean (±SE) values for pulmonary-artery systolic pressure (51.9±4.1 mm Hg), diastolic pressure (26.1±2.16 mm Hg), mean pulmonary-artery pressure (34.5±2.7 mm Hg), pulmonary-artery wedge pressure (17.2±1.2 mm Hg), cardiac output (10.2±0.7 liters per minute as measured by thermodilution and 9.6±0.4 liters per minute as calculated with the Fick equation), and pulmonary vascular resistance (148.5±26.2 dyn
sec
Survival
Among the 195 patients, 5 were lost to follow-up: all had a tricuspid regurgitant jet velocity of less than 2.5 m per second. Death certificates were used to confirm the death of any patient. No death certificates were found for these five patients who were lost to follow-up, suggesting that they are still living. The median follow-up was 18.3 months for the 128 patients with a tricuspid regurgitant jet velocity of less than 2.5 m per second and 17.3 months for the 62 patients with a tricuspid regurgitant jet velocity of at least 2.5 m per second.
Proportional-hazards regression analysis showed that patients with a tricuspid regurgitant jet velocity of at least 2.5 m per second had a significantly higher mortality rate than those with a jet velocity of less than 2.5 m per second (P<0.001) (Figure 2Figure 2
Kaplan–Meier Survival Curves According to the Tricuspid Regurgitant Jet Velocity.); the rate ratio for death was 10.1 (95 percent confidence interval, 2.2 to 47.0). Analyses were also performed separately for age, cardiac output, stroke volume, the ratio for the E wave to the A wave, deceleration time, isovolumic relaxation time, hemoglobin level, fetal hemoglobin level, lactate dehydrogenase level, white-cell count, and creatinine level. Besides the tricuspid regurgitant jet velocity, the only significant univariate correlate of the risk of death was the creatinine level (P=0.007). After adjustment for the tricuspid regurgitant jet velocity, the creatinine level was not significantly related to the risk of death (P=0.08), whereas the jet velocity remained a significant independent correlate (P=0.004).Because we were concerned that pulmonary hypertension conferred a substantial risk of death, the study was not designed as a natural-history study. Patients and referring physicians were made aware of the results of echocardiography, and the patients who were identified as having severe pulmonary hypertension (on the basis of a tricuspid regurgitant jet velocity of at least 3.0 m per second) were offered treatments such as exchange transfusion, oxygen, and selective pulmonary vasodilator therapy according to a National Heart, Lung, and Blood Institute protocol. Eleven of the 17 patients with a tricuspid regurgitant jet velocity of at least 3.0 m per second began either an aggressive exchange-transfusion program or inhaled nitric oxide therapy after pulmonary hypertension was diagnosed, and 10 of these patients are still alive.
Discussion
We found that the prevalence of pulmonary hypertension among patients with sickle cell disease was 32 percent, which is consistent with previously published retrospective studies. Despite having lower pulmonary-artery pressures and higher cardiac outputs than patients with primary pulmonary hypertension, patients with sickle cell disease and pulmonary hypertension had a significantly higher mortality rate than did patients with sickle cell disease who did not have pulmonary hypertension, a finding that is consistent with the results of previous retrospective studies.6,10,11,13 Our findings suggest that the noninvasive measurement of tricuspid regurgitant jet velocity by echocardiography can be used to identify patients at high risk for death and may thus be viewed as a prognostic tool analogous to transcranial carotid Doppler flow-velocity assessment, which is used to predict the risk of stroke in children with sickle cell disease.24
The observation that markers of hemolysis are associated with pulmonary hypertension provides a link between sickle cell disease and other chronic hemolytic disorders and suggests that there is a distinct syndrome of hemolysis-associated pulmonary hypertension. Thalassemia, for example, is another chronic hemolytic disease that is associated with secondary pulmonary hypertension; the prevalence of pulmonary hypertension among patients with thalassemia ranges from 10 percent to 93 percent, depending on the patient population studied.2,25-28 Patients with sickle cell disease and patients with thalassemia both have chronic hemolysis, which results in the release of hemoglobin into plasma. Plasma hemoglobin can scavenge nitric oxide as well as catalyze the formation of reactive oxygen and nitrogen species, processes that can lead to acute and chronic pulmonary vasoconstriction.29 Hemolysis could also release erythrocyte arginase, as suggested by recent reports that arginase activity may be increased (a possibility that is consistent with our finding that arginine:ornithine ratios were significantly lower in patients than in control subjects) and that the bioavailability of arginine and nitric oxide is reduced in patients with sickle cell disease.29-33 Hemoglobin-induced scavenging of nitric oxide results in transcriptional up-regulation of adhesion molecules such as vascular-cell adhesion molecule 1 and E-selectin and induces the expression of endothelin-1, a potent vasoconstrictor.33-35 Indeed, endothelin-1 levels are elevated in the plasma of patients with primary pulmonary hypertension and patients with sickle cell disease.36,37 The statistical linkage among pulmonary hypertension, systolic systemic hypertension, and the hemolytic rate (associated with nitric oxide scavenging29) is consistent with previous clinical observations that systemic hypertension is a risk factor for stroke and early death in patients with sickle cell disease.38-40
Additional insults common to sickle cell disease and thalassemia that might lead to end-organ dysfunction and pulmonary hypertension include iron deposition, cirrhosis, anemia with a high cardiac-output state, and asplenism. Although cirrhosis can result in secondary pulmonary hypertension, cirrhosis and hepatic synthetic dysfunction were not common in our patients with pulmonary hypertension. It is unclear whether the significant increases in alkaline phosphatase and direct bilirubin in patients with pulmonary hypertension were due to more subtle liver dysfunction or to a secondary effect of pulmonary hypertension and increased passive liver congestion. The absence of an association between cardiac output and tricuspid regurgitant jet velocity in our study argues against a role for chronic anemia and a high cardiac-output state, leading to vascular remodeling and arteriopathy. If anemia itself were responsible, one would expect to find reports of pulmonary hypertension associated with iron-deficiency anemia, the most common cause of anemia in the world.
We were surprised that hydroxyurea therapy was not associated with lower tricuspid regurgitant jet velocity and that there was no significant association between the fetal hemoglobin level or the white-cell count and tricuspid regurgitant jet velocity; both are independent markers of disease severity and predictors of the outcome in sickle cell disease.41 Although neither prospective nor randomized, our study suggests that hydroxyurea and other drugs that increase the expression of fetal hemoglobin may not prevent pulmonary hypertension. We speculate that this may be explained by the relatively limited induction of fetal hemoglobin associated with such therapy, the lack of full fetal-cell penetrance, and the presence of persistent hemolysis in most of our patients. Analysis of polymerization tendencies suggests that fetal hemoglobin levels of more than 25 percent in a pancellular distribution would be required to eliminate intracellular polymerization and hemolysis.42,43 This possibility is supported by the observation that hemoglobin C, which is present in all erythrocytes and reduces the rate of hemolysis, was associated with a reduced tricuspid regurgitant jet velocity.
In conclusion, pulmonary hypertension is common in adults with sickle cell disease and is associated with an ominous outcome. Our results support the use of Doppler echocardiographic screening in all adults with sickle cell disease to identify a high-risk group that may benefit from intervention. Therapeutic trials of oxygen, warfarin, transfusion, and pulmonary vasodilator and remodeling medications are urgently required to evaluate their potential to decrease the substantial morbidity and mortality associated with pulmonary hypertension in this population.
Supported by intramural funds from the Clinical Center, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Heart, Lung, and Blood Institute; the Center for Research on Minority Health and Health Disparities; and a Collaborative Research and Development Agreement with INO Therapeutics, (Clinton, N.J.).
We are indebted to the respiratory therapy, nursing, and physician staffs of the Critical Care Medicine Department and 7 East Unit of the Clinical Center, National Institutes of Health, and to Mary K. Hall for assistance with the protocol.
Source Information
From the Critical Care Medicine Department, Clinical Center (M.T.G., M.L.J., K.M., W.A.C., J.S.N., I.E., L.A.H., W.C.B., F.P.O.), the Cardiovascular Branch, National Heart, Lung, and Blood Institute (M.T.G., V.S., Y.S., J.F.P., I.E.), and the Laboratory of Chemical Biology (M.T.G., A.N.S.) and the Molecular and Clinical Hematology Branch (G.P.R.), National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md.; and the Cardiology Division, Department of Medicine (B.B.), and the Center for Sickle Cell Disease (O.C.), Howard University College of Medicine, Washington, D.C.
Address reprint requests to Dr. Gladwin at the National Institutes of Health, Bldg. 10, Rm. 7D-43, 10 Center Dr., Bethesda, MD 20892-1662, or at mgladwin@nih.gov.
- References
References
1
Collins FS ,Orringer EP . Pulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med 1982;73:814-821
CrossRef | Web of Science | Medline2
Aessopos A ,Farmakis D ,Karagiorga M , et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001;97:3411-3416
CrossRef | Web of Science | Medline3
Hayag-Barin JE ,Smith RE ,Tucker FC Jr . Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol 1998;57:82-84
CrossRef | Web of Science | Medline4
Heller PG ,Grinberg AR ,Lencioni M ,Molina MM ,Roncoroni AJ . Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. Chest 1992;102:642-643
CrossRef | Web of Science | Medline5
Haque AK ,Gokhale S ,Rampy BA ,Adegboyega P ,Duarte A ,Saldana MJ . Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol 2002;33:1037-1043
CrossRef | Web of Science | Medline6
Castro OL ,Hoque M ,Brown BD . Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2002;101:1257-1261
CrossRef | Web of Science | Medline7
Adedeji MO ,Cespedes J ,Allen K ,Subramony C ,Hughson MD . Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001;125:1436-1441
Web of Science | Medline8
Norris SL ,Johnson C ,Haywood LJ . Left ventricular filling pressure in sickle cell anemia. J Assoc Acad Minor Phys 1992;3:20-23
Medline9
Simmons BE ,Santhanam V ,Castaner A ,Rao KR ,Sachdev N ,Cooper R . Sickle cell heart disease: two-dimensional echo and Doppler ultrasonographic findings in the hearts of adult patients with sickle cell anemia. Arch Intern Med 1988;148:1526-1528
CrossRef | Web of Science | Medline10
Van Enk A ,Visschers G ,Jansen W ,Statius van Eps LW . Maternal death due to sickle cell chronic lung disease. Br J Obstet Gynaecol 1992;99:162-163
CrossRef | Medline11
Sutton LL ,Castro O ,Cross DJ ,Spencer JE ,Lewis JF . Pulmonary hypertension in sickle cell disease. Am J Cardiol 1994;74:626-628
CrossRef | Web of Science | Medline12
Castro O . Systemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am 1996;10:1289-1303
CrossRef | Web of Science | Medline13
Powars D ,Weidman JA ,Odom-Maryon T ,Niland JC ,Johnson C . Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988;67:66-76
Web of Science | Medline14
Escoffery CT ,Shirley SE . Causes of sudden natural death in Jamaica: a medicolegal (coroner's) autopsy study from the University Hospital of the West Indies. Forensic Sci Int 2002;129:116-121
CrossRef | Web of Science | Medline15
Liesner RJ ,Vandenberghe EA . Sudden death in sickle cell disease. J R Soc Med 1993;86:484-485
Web of Science | Medline16
Schiller NB ,Shah PM ,Crawford M , et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-367
Medline17
Appleton CP ,Jensen JL ,Hatle LK ,Oh JK . Doppler evaluation of left and right ventricular diastolic function: a technical guide for obtaining optimal flow velocity recordings. J Am Soc Echocardiogr 1997;10:271-292
CrossRef | Web of Science | Medline18
Chopra HK ,Nanda NC ,Fan P , et al. Can two-dimensional echocardiography and Doppler color flow mapping identify the need for tricuspid valve repair? J Am Coll Cardiol 1989;14:1266-1274
CrossRef | Web of Science | Medline19
Lewis JF ,Kuo LC ,Nelson JG ,Limacher MC ,Quinones MA . Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window. Circulation 1984;70:425-431
CrossRef | Web of Science | Medline20
Quinones MA ,Otto CM ,Stoddard M ,Waggoner A ,Zoghbi WA . Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15:167-184
CrossRef | Web of Science | Medline21
Berger M ,Haimowitz A ,Van Tosh A ,Berdoff RL ,Goldberg E . Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6:359-365
CrossRef | Web of Science | Medline22
Kircher BJ ,Himelman RB ,Schiller NB . Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol 1990;66:493-496
CrossRef | Web of Science | Medline23
Rubin LJ . Primary pulmonary hypertension. N Engl J Med 1997;336:111-117
Full Text | Web of Science | Medline24
Adams RJ ,McKie VC ,Hsu L , et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11
Full Text | Web of Science | Medline25
Du ZD ,Roguin N ,Milgram E ,Saab K ,Koren A . Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997;134:532-537
CrossRef | Web of Science | Medline26
Hahalis G ,Manolis AS ,Apostolopoulos D ,Alexopoulos D ,Vagenakis AG ,Zoumbos NC . Right ventricular cardiomyopathy in beta-thalassaemia major. Eur Heart J 2002;23:147-156
CrossRef | Web of Science | Medline27
Derchi G ,Fonti A ,Forni GL , et al. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1999;138:384-384
CrossRef | Web of Science | Medline28
Grisaru D ,Rachmilewitz EA ,Mosseri M , et al. Cardiopulmonary assessment in beta-thalassemia major. Chest 1990;98:1138-1142
CrossRef | Web of Science | Medline29
Reiter CD ,Wang X ,Tanus-Santos JE , et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002;8:1383-1389
CrossRef | Web of Science | Medline30
Morris CR ,Kuypers FA ,Larkin S ,Vichinsky EP ,Styles LA . Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hematol Oncol 2000;22:515-520
CrossRef | Web of Science | Medline31
Morris CR ,Morris SM Jr ,Hagar W , et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69
CrossRef | Web of Science | Medline32
Aslan M ,Ryan TM ,Adler B , et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A 2001;98:15215-15220
CrossRef | Web of Science | Medline33
Gladwin MT ,Schechter AN ,Ognibene FP , et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 2003;107:271-278
CrossRef | Web of Science | Medline34
De Caterina R ,Libby P ,Peng HB , et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-68
CrossRef | Web of Science | Medline35
Lin G ,Macdonald RL ,Marton LS ,Kowalczuk A ,Solenski NJ ,Weir BK . Hemoglobin increases endothelin-1 in endothelial cells by decreasing nitric oxide. Biochem Biophys Res Commun 2001;280:824-830
CrossRef | Web of Science | Medline36
Hammerman SI ,Kourembanas S ,Conca TJ ,Tucci M ,Brauer M ,Farber HW . Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 1997;156:280-285
Web of Science | Medline37
Rybicki AC ,Benjamin LJ . Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood 1998;92:2594-2596
Web of Science | Medline38
Rodgers GP ,Walker EC ,Podgor MJ . Is “relative“ hypertension a risk factor for vaso-occlusive complications in sickle cell disease? Am J Med Sci 1993;305:150-156
CrossRef | Web of Science | Medline39
Pegelow CH ,Colangelo L ,Steinberg M , et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med 1997;102:171-177
CrossRef | Web of Science | Medline40
Ohene-Frempong K ,Weiner SJ ,Sleeper LA , et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-294
Web of Science | Medline41
Platt OS ,Brambilla DJ ,Rosse WF , et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644
Full Text | Web of Science | Medline42
Atweh GF ,Schechter AN . Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 2001;8:123-130
CrossRef | Web of Science | Medline43
Noguchi CT ,Rodgers GP ,Serjeant G ,Schechter AN . Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988;318:96-99
Full Text | Web of Science | Medline
- Citing Articles (267)
Citing Articles
1
Scott Roberts. 2012. Sickle Cell Anemia. , 93-97.
CrossRef2
Janet I. Malowany, Jagdish Butany. (2012) Pathology of sickle cell disease. Seminars in Diagnostic Pathology 29:1, 49-55
CrossRef3
P. M. Bauer, E. M. Bauer, N. M. Rogers, M. Yao, M. Feijoo-Cuaresma, J. M. Pilewski, H. C. Champion, B. S. Zuckerbraun, M. J. Calzada, J. S. Isenberg. (2012) Activated CD47 Promotes Pulmonary Arterial Hypertension Through Targeting Caveolin-1. Cardiovascular Research
CrossRef4
Helen R Levey, Omer Kutlu, Trinity J Bivalacqua. (2012) Medical management of ischemic stuttering priapism: a contemporary review of the literature. Asian Journal of Andrology 14:1, 156-163
CrossRef5
Benjamin D. Fox, Toshika Okumiya, Liat Attas-Fox, Michael Kassirer, Yael Raviv, Mordechai R. Kramer. (2012) Raised erythrocyte creatine in patients with pulmonary arterial hypertension – Evidence for subclinical hemolysis. Respiratory Medicine
CrossRef6
E. Vlachaki, A. Kalogeridis, N. Neokleous, V. Perifanis, F. Klonizakis, E. Ioannidou, I. Klonizakis. (2011) Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy. Molecular Biology Reports
CrossRef7
J Freed, J Talano, T Small, A Ricci, M S Cairo. (2011) Allogeneic cellular and autologous stem cell therapy for sickle cell disease: ‘whom, when and how’. Bone Marrow Transplantation
CrossRef8
Mark T Gladwin. (2011) Prevalence, risk factors and mortality of pulmonary hypertension defined by right heart catheterization in patients with sickle cell disease. Expert Review of Hematology 4:6, 593-596
CrossRef9
Mehran Karimi, Khaled M. Musallam, Maria Domenica Cappellini, Shahina Daar, Amal El-Beshlawy, Khawla Belhoul, Mohamed-SalahEldin Saned, Sally Temraz, Suzanne Koussa, Ali T. Taher. (2011) Risk factors for pulmonary hypertension in patients with β thalassemia intermedia. European Journal of Internal Medicine 22:6, 607-610
CrossRef10
Mae M. Centeno. (2011) Pulmonary Arterial Hypertension. Critical Care Nursing Clinics of North America 23:4, 645-659
CrossRef11
S. Shenoy. (2011) Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: Current Practice and Emerging Trends. Hematology 2011:1, 273-279
CrossRef12
K. L. Hassell. (2011) Pulmonary Hypertension, Tricuspid Regurgitant Velocity Screening, and the Nitric Oxide Pathway. Hematology 2011:1, 419-426
CrossRef13
Jessica E. Knight-Perry, Lisa de las Fuentes, Alan D. Waggoner, Raymond G. Hoffmann, Morey A. Blinder, Victor G. Dávila-Román, Joshua J. Field. (2011) Abnormalities in Cardiac Structure and Function in Adults with Sickle Cell Disease are not Associated with Pulmonary Hypertension. Journal of the American Society of Echocardiography 24:11, 1285-1290
CrossRef14
Nicolas Leveziel, Sylvie Bastuji-Garin, Franck Lalloum, Giuseppe Querques, Pascale Benlian, Michel Binaghi, Gabriel Coscas, Gisèle Soubrane, Dora Bachir, Frédéric Galactéros, Eric H. Souied. (2011) Clinical and Laboratory Factors Associated With the Severity of Proliferative Sickle Cell Retinopathy in Patients With Sickle Cell Hemoglobin C (SC) and Homozygous Sickle Cell (SS) Disease. Medicine 90:6, 372-378
CrossRef15
David C. Rees, John S. Gibson. (2011) Biomarkers in sickle cell disease. British Journal of Haematologyno-no
CrossRef16
Jo Howard, Eugene Oteng-Ntim. (2011) The obstetric management of sickle cell disease. Best Practice & Research Clinical Obstetrics & Gynaecology
CrossRef17
Shinichi Takatsuki, David Dunbar Ivy, Rachelle Nuss. (2011) Correlation of N-Terminal Fragment of B-type Natriuretic Peptide Levels with Clinical, Laboratory, and Echocardiographic Abnormalities in Children with Sickle Cell Disease. The Journal of Pediatrics
CrossRef18
(2011) Pulmonary Hypertension in Sickle Cell Disease. New England Journal of Medicine 365:17, 1645-1649
Full Text19
C. R. Morris, H.-Y. Kim, F. Trachtenberg, J. Wood, C. T. Quinn, N. Sweeters, J. L. Kwiatkowski, A. A. Thompson, P. J. Giardina, J. Boudreaux, N. F. Olivieri, J. B. Porter, E. J. Neufeld, E. P. Vichinsky, . (2011) Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood 118:14, 3794-3802
CrossRef20
D. G. Nathan. (2011) Guilt by association. Blood 118:14, 3758-3759
CrossRef21
Swee Lay Thein. (2011) Genetic Modifiers of Sickle Cell Disease. Hemoglobin 35:5-6, 589-606
CrossRef22
Samir K. Ballas. (2011) Defining the Phenotypes of Sickle Cell Disease. Hemoglobin 35:5-6, 511-519
CrossRef23
Ruby A. Khoury, Khaled M. Musallam, Salman Mroueh, Miguel R. Abboud. (2011) Pulmonary Complications of Sickle Cell Disease. Hemoglobin 35:5-6, 625-635
CrossRef24
G. Quéré, A. Tempescul, F. Couturaud, N. Paleiron, C. Leroyer, L. De Saint-Martin. (2011) Le syndrome thoracique aigu de l’adulte drépanocytaire. Revue de Pneumologie Clinique
CrossRef25
Gavin Cho, Ian R Hambleton, Gavin Cho. 2011. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. .
CrossRef26
Robyn T. Cohen, Anusha Madadi, Morey A. Blinder, Michael R. DeBaun, Robert C. Strunk, Joshua J. Field. (2011) Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. American Journal of Hematology 86:9, 756-761
CrossRef27
Rabindra N. Paul, Oswaldo L. Castro, Anita Aggarwal, Patricia A. Oneal. (2011) Acute chest syndrome: sickle cell disease. European Journal of Haematology 87:3, 191-207
CrossRef28
Paul T. Cutrufello, Kenneth W. Rundell, James M. Smoliga, Georgios A. Stylianides. (2011) Inhaled whole exhaust and its effect on exercise performance and vascular function. Inhalation Toxicology 23:11, 658-667
CrossRef29
Hooman Mirzakhani, Ala Nozari. 2011. Ischemia. , 145-158.
CrossRef30
M. M. Hsieh, C. D. Fitzhugh, J. F. Tisdale. (2011) Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 118:5, 1197-1207
CrossRef31
Roberto F. Machado, Mariana Hildesheim, Laurel Mendelsohn, Alan T. Remaley, Gregory J. Kato, Mark T. Gladwin. (2011) NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease. British Journal of Haematology 154:4, 512-520
CrossRef32
Katerina Pavenski, Elianna Saidenberg, Marianne Lavoie, Melanie Tokessy, Donald R. Branch. (2011) Red Blood Cell Storage Lesions and Related Transfusion Issues: A Canadian Blood Services Research and Development Symposium. Transfusion Medicine Reviews
CrossRef33
R. F. Machado, R. J. Barst, N. A. Yovetich, K. L. Hassell, G. J. Kato, V. R. Gordeuk, J. S. R. Gibbs, J. A. Little, D. E. Schraufnagel, L. Krishnamurti, R. E. Girgis, C. R. Morris, E. B. Rosenzweig, D. B. Badesch, S. Lanzkron, O. Onyekwere, O. L. Castro, V. Sachdev, M. A. Waclawiw, R. Woolson, J. C. Goldsmith, M. T. Gladwin, . (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 118:4, 855-864
CrossRef34
Parent, Florence, Bachir, Dora, Inamo, Jocelyn, Lionnet, François, Driss, Françoise, Loko, Gylna, Habibi, Anoosha, Bennani, Soumiya, Savale, Laurent, Adnot, Serge, Maitre, Bernard, Yaïci, Azzedine, Hajji, Leila, O'Callaghan, Dermot S., Clerson, Pierre, Girot, Robert, Galacteros, Frederic, Simonneau, Gerald, . (2011) A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease. New England Journal of Medicine 365:1, 44-53
Full Text35
Ward Hagar, Claudia R. Morris. 2011. Adults with Sickle-Cell Disease: Implications of Increasing Longevity. , 115-140.
CrossRef36
P. Y. Hsue, A. F. Bolger, J. N. Martin. (2011) Pulmonary Hypertension in HIV-Infected Individuals. Clinical Infectious Diseases 53:1, 96-96
CrossRef37
Ruby Khoury, Miguel R Abboud. (2011) Stem-cell transplantation in children and adults with sickle cell disease: an update. Expert Review of Hematology 4:3, 343-351
CrossRef38
Nadia Solovieff, Stephen W. Hartley, Clinton T. Baldwin, Elizabeth S. Klings, Mark T. Gladwin, James G. Taylor, Gregory J. Kato, Lindsay A. Farrer, Martin H. Steinberg, Paola Sebastiani. (2011) Ancestry of African Americans with sickle cell disease. Blood Cells, Molecules, and Diseases 47:1, 41-45
CrossRef39
Gregory J. Kato. (2011) Priapism in Sickle-Cell Disease: A Hematologist's Perspective. The Journal of Sexual Medicineno-no
CrossRef40
Clément Tassel, Cécile Arnaud, Marc Kulpa, Emmanuelle Fleurence, Annie Kandem, Fouad Madhi, Françoise Bernaudin, Christophe Delacourt. (2011) Leukocytosis is a risk factor for lung function deterioration in children with sickle cell disease. Respiratory Medicine 105:5, 788-795
CrossRef41
Holger Jon Moller, Marianne Jensby Nielsen, Jack Bartram, Moira C. Dick, Susan E. Height, Soren K. Moestrup, David C. Rees. (2011) Soluble CD163 levels in children with sickle cell disease. British Journal of Haematology 153:1, 105-110
CrossRef42
Warren A Zuckerman, Erika B Rosenzweig. (2011) Pulmonary hypertension in children with sickle cell disease. Expert Review of Respiratory Medicine 5:2, 233-243
CrossRef43
Daniel B. Kim-Shapiro, Janet Lee, Mark T. Gladwin. (2011) Storage lesion: role of red blood cell breakdown. Transfusion 51:4, 844-851
CrossRef44
Robert P. Hebbel. (2011) Reconstructing sickle cell disease: A data-based analysis of the “hyperhemolysis paradigm” for pulmonary hypertension from the perspective of evidence-based medicine. American Journal of Hematology 86:2, 123-154
CrossRef45
James R. Eckman, Stephen H. Embury. (2011) Sickle cell anemia pathophysiology: Back to the data. American Journal of Hematology 86:2, 121-122
CrossRef46
Kenneth I. Ataga, Julia E. Brittain, Susan K. Jones, Ryan May, John Delaney, Dell Strayhorn, Payal Desai, Rupa Redding-Lallinger, Nigel S. Key, Eugene P. Orringer. (2011) Association of soluble fms-like tyrosine kinase-1 with pulmonary hypertension and haemolysis in sickle cell disease. British Journal of Haematology 152:4, 485-491
CrossRef47
Daniel Lorch, Daniel Spevack, Jane Little. (2011) An Elevated Estimated Pulmonary Arterial Systolic Pressure, Whenever Measured, Is Associated with Excess Mortality in Adults with Sickle Cell Disease. Acta Haematologica 125:4, 225-229
CrossRef48
Suzanne Forrest, Ashley Kim, Judith Carbonella, Farzana Pashankar. (2011) Proteinuria is associated with elevated tricuspid regurgitant jet velocity in children with sickle cell disease. Pediatric Blood & Cancern/a-n/a
CrossRef49
Lynne G. Maxwell, Salvatore R. Goodwin, Thomas J. Mancuso, Victor C. Baum, Aaron L. Zuckerberg, Philip G. Morgan, Etsuro K. Motoyama, Peter J. Davis, Kevin J. Sullivan. 2011. Systemic Disorders. , 1098-1182.
CrossRef50
Gregory J. Kato. (2011) TRV: A physiological biomarker in sickle cell disease. Pediatric Blood & Cancern/a-n/a
CrossRef51
M.A. Bender, Katie R. Nielsen. 2011. Hemoglobinopathies. , 1191-1206.
CrossRef52
Bryan Corrin, Andrew G. Nicholson. 2011. Vascular disease. , 401-457.
CrossRef53
Bryan Corrin, Andrew G. Nicholson. 2011. Pulmonary manifestations of systemic disease. , 471-507.
CrossRef54
K. L. Wallace, J. Linden. (2010) Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 116:23, 5010-5020
CrossRef55
Susan Yuditskaya, Anthony F Suffredini, Gregory J Kato. (2010) The proteome of sickle cell disease: insights from exploratory proteomic profiling. Expert Review of Proteomics 7:6, 833-848
CrossRef56
Iryna Rusanova, Germaine Escames, Gladys Cossio, Rosaura G. De Borace, Belgica Moreno, Mariam Chahboune, Luís C. López, Tomas Díez, Dario Acuña-Castroviejo. (2010) Oxidative stress status, clinical outcome, and β-globin gene cluster haplotypes in pediatric patients with sickle cell disease. European Journal of Haematology 85:6, 529-537
CrossRef57
David C Rees, Thomas N Williams, Mark T Gladwin. (2010) Sickle-cell disease. The Lancet 376:9757, 2018-2031
CrossRef58
Colm J. Murphy, Gavin Y. Oudit. (2010) Iron-Overload Cardiomyopathy: Pathophysiology, Diagnosis, and Treatment. Journal of Cardiac Failure 16:11, 888-900
CrossRef59
Kevin Joseph Sullivan, Niranjan Kissoon, Eric Sandler, Cynthia Gauger, Melanie Froyen, Laurie Duckworth, Martha Brown, Suzanne Murphy. (2010) Effect of Oral Arginine Supplementation on Exhaled Nitric Oxide Concentration in Sickle Cell Anemia and Acute Chest Syndrome. Journal of Pediatric Hematology/Oncology 32:7, e249-e258
CrossRef60
Robert I. Liem, Luciana T. Young, Amy S. Lay, Stephanie A. Pelligra, Richard J. Labotka, Alexis A. Thompson. (2010) Reproducibility of tricuspid regurgitant jet velocity measurements in children and young adults with sickle cell disease undergoing screening for pulmonary hypertension. American Journal of Hematology 85:10, 741-745
CrossRef61
W. Hu, R. Jin, J. Zhang, T. You, Z. Peng, X. Ge, R. T. Bronson, J. A. Halperin, J. Loscalzo, X. Qin. (2010) The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood 116:9, 1613-1622
CrossRef62
Kenneth I. Ataga, Julia E. Brittain, Dominic Moore, Susan K. Jones, Ben Hulkower, Dell Strayhorn, Soheir Adam, Rupa Redding-Lallinger, Patrick Nachman, Eugene P. Orringer. (2010) Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1. European Journal of Haematology 85:3, 257-263
CrossRef63
Grazielle Mecabo, Debora Yumi Hayashida, Marily Maria Azevedo-Shimmoto, Perla Vicari, Martha Mariana de Almeida Santos Arruda, José Orlando Bordin, Maria Stella Figueiredo. (2010) Duffy-negative is associated with hemolytic phenotype of sickle cell anemia. Clinical Immunology 136:3, 458-459
CrossRef64
Keith Quirolo. (2010) How do I transfuse patients with sickle cell disease?. Transfusion 50:9, 1881-1886
CrossRef65
Stephanie J. Kelly, Shalabh Singhal, Jean M. Elwing, Yukitaka Shizukuda. (2010) Characteristics of Exercise-Induced Intrapulmonary Arteriovenous Fistula in Patients with Unexplained Exertional Dyspnea. Echocardiography 27:8, 908-913
CrossRef66
Raffaella Colombatti, Nicola Maschietto, Elena Varotto, Alessandra Grison, Nicoletta Grazzina, Linda Meneghello, Simone Teso, Modesto Carli, Ornella Milanesi, Laura Sainati. (2010) Pulmonary hypertension in sickle cell disease children under 10 years of age. British Journal of Haematology 150:5, 601-609
CrossRef67
Idowu Akinsheye, Elizabeth S. Klings. (2010) Sickle cell anemia and vascular dysfunction: The nitric oxide connection. Journal of Cellular Physiology 224:3, 620-625
CrossRef68
H. F. Bunn, D. G. Nathan, G. J. Dover, R. P. Hebbel, O. S. Platt, W. F. Rosse, R. E. Ware. (2010) Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 116:5, 687-692
CrossRef69
M. T. Gladwin, R. J. Barst, O. L. Castro, V. R. Gordeuk, C. A. Hillery, G. J. Kato, D. B. Kim-Shapiro, R. Machado, C. R. Morris, M. H. Steinberg, E. P. Vichinsky. (2010) Pulmonary hypertension and NO in sickle cell. Blood 116:5, 852-854
CrossRef70
Kleber Yotsumoto Fertrin, Fernando Ferreira Costa. (2010) Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment. Expert Review of Hematology 3:4, 443-458
CrossRef71
Danitza Nebor, Cédric Broquere, Karine Brudey, Danielle Mougenel, Vanessa Tarer, Philippe Connes, Jacques Elion, Marc Romana. (2010) Alpha-thalassemia is associated with a decreased occurrence and a delayed age-at-onset of albuminuria in sickle cell anemia patients. Blood Cells, Molecules, and Diseases 45:2, 154-158
CrossRef72
Claudia R. Morris, Elliott P. Vichinsky. (2010) Pulmonary hypertension in thalassemia. Annals of the New York Academy of Sciences 1202:1, 205-213
CrossRef73
V. Audard, S. Homs, A. Habibi, F. Galacteros, P. Bartolucci, B. Godeau, B. Renaud, Y. Levy, P. Grimbert, P. Lang, C. Brun-Buisson, L. Brochard, F. Schortgen, B. Maitre, A. Mekontso Dessap. (2010) Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrology Dialysis Transplantation 25:8, 2524-2529
CrossRef74
G. J. Kato, V. Sachdev. (2010) Diastolic dysfunction in sickle cell. Blood 116:1, 1-2
CrossRef75
M. C. Johnson, F. J. Kirkham, S. Redline, C. L. Rosen, Y. Yan, I. Roberts, J. Gruenwald, J. Marek, M. R. DeBaun. (2010) Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation. Blood 116:1, 16-21
CrossRef76
N. Sundaram, A. Tailor, L. Mendelsohn, J. Wansapura, X. Wang, T. Higashimoto, M. W. Pauciulo, W. Gottliebson, V. K. Kalra, W. C. Nichols, G. J. Kato, P. Malik. (2010) High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood 116:1, 109-112
CrossRef77
Charlotte F.J. van Tuijn, Eduard J. van Beers, John-John B. Schnog, Bart J. Biemond. (2010) Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. American Journal of Hematology 85:7, 532-535
CrossRef78
Richard N. Channick. (2010) Pulmonary hypertension: Classification and treatment. Canadian Journal of Cardiology 26, 5B-11B
CrossRef79
Anita Hill, Russell P. Rother, Xunde Wang, Sidney M. Morris, Jr, Kerry Quinn-Senger, Richard Kelly, Stephen J. Richards, Monica Bessler, Leonard Bell, Peter Hillmen, Mark T. Gladwin. (2010) Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 149:3, 414-425
CrossRef80
Robyn J. Barst, Kamal K. Mubarak, Roberto F. Machado, Kenneth I. Ataga, Raymond L. Benza, Oswaldo Castro, Robert Naeije, Namita Sood, Paul S. Swerdlow, Mariana Hildesheim, Mark T. Gladwin, . (2010) Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. British Journal of Haematology 149:3, 426-435
CrossRef81
G. A. Laurie. (2010) Acute chest syndrome in sickle cell disease. Internal Medicine Journal 40:5, 372-376
CrossRef82
Suzana Zorca, Lita Freeman, Mariana Hildesheim, Darlene Allen, Alan T. Remaley, James G. Taylor, Gregory J. Kato. (2010) Lipid levels in sickle-cell disease associated with haemolytic severity, vascular dysfunction and pulmonary hypertension. British Journal of Haematology 149:3, 436-445
CrossRef83
Glenda M. Ninkovich, Sally K. Miller, Patricia T. Alpert. (2010) Sickle-cell anemia and pulmonary hypertension. Journal of the American Academy of Nurse Practitioners 22:4, 198-204
CrossRef84
P.P. Landburg, T. Teerlink, B.J. Biemond, D.P.M. Brandjes, F.A.J. Muskiet, A.J. Duits, J.B. Schnog. (2010) Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype. Blood Cells, Molecules, and Diseases 44:4, 229-232
CrossRef85
Zakari Y. Aliyu, Aisha Suleiman, Ester Attah, Aisha I. Mamman, Aliyu Babadoko, Mehdi Nouraie, Laurel Mendelsohn, Gregory J. Kato, Victor R. Gordeuk, Mark T. Gladwin. (2010) NT-proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa. British Journal of Haematology
CrossRef86
Gregory J. Kato, James G. Taylor. (2010) Pleiotropic effects of intravascular haemolysis on vascular homeostasis. British Journal of Haematology 148:5, 690-701
CrossRef87
Binglan Yu, Mohd Shahid, Elena M. Egorina, Mikhail A. Sovershaev, Michael J. Raher, Chong Lei, Mei X. Wu, Kenneth D. Bloch, Warren M. Zapol. (2010) Endothelial Dysfunction Enhances Vasoconstriction Due to Scavenging of Nitric Oxide by a Hemoglobin-based Oxygen Carrier. Anesthesiology 112:3, 586-594
CrossRef88
Hanane A. Dahoui, Munya N. Hayek, Paul J. Nietert, Mariam T. Arabi, Samar A. Muwakkit, Raya H. Saab, Abdallah N. Bissar, Nidal M. Jumaa, Fadi S. Farhat, Ibrahim A. Dabbous, Fadi F. Bitar, Miguel R. Abboud. (2010) Pulmonary hypertension in children and young adults with sickle cell disease: Evidence for familial clustering. Pediatric Blood & Cancer 54:3, 398-402
CrossRef89
Gavin Cho, Ian R Hambleton, Gavin Cho. 2010. Regular long-term red blood cell transfusions for managing chronic chest complications in sickle cell disease. .
CrossRef90
Mark C. Walters, Karen Hardy, Sandie Edwards, Thomas Adamkiewicz, James Barkovich, Francoise Bernaudin, George R. Buchanan, Nancy Bunin, Roswitha Dickerhoff, Roger Giller, Paul R. Haut, John Horan, Lewis L. Hsu, Naynesh Kamani, John E. Levine, David Margolis, Kwaku Ohene-Frempong, Melinda Patience, Rupa Redding-Lallinger, Irene A.G. Roberts, Zora R. Rogers, Jean E. Sanders, J. Paul Scott, Keith M. Sullivan. (2010) Pulmonary, Gonadal, and Central Nervous System Status after Bone Marrow Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation 16:2, 263-272
CrossRef91
Matthew M. Heeney, Russell E. Ware. (2010) Hydroxyurea for Children with Sickle Cell Disease. Hematology/Oncology Clinics of North America 24:1, 199-214
CrossRef92
Gwenola Maigne, Sophie Ferlicot, Frederic Galacteros, Xavier Belenfant, Tim Ulinski, Patrick Niaudet, Pierre Ronco, Bertrand Godeau, Antoine Durrbach, Sabrinel Sahali, Philippe Lang, Olivier Lambotte, Vincent Audard. (2010) Glomerular Lesions in Patients With Sickle Cell Disease. Medicine 89:1, 18-27
CrossRef93
Marius George Linguraru, John A. Pura, Robert L. Van Uitert, Nisha Mukherjee, Ronald M. Summers, Caterina Minniti, Mark T. Gladwin, Gregory Kato, Roberto F. Machado, Bradford J. Wood. (2010) Segmentation and quantification of pulmonary artery for noninvasive CT assessment of sickle cell secondary pulmonary hypertension. Medical Physics 37:4, 1522
CrossRef94
Joshua J. Field, Anusha R. Madadi, Marilyn J. Siegel, Vamsidhar Narra. (2010) Author response letter to: âPulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated tricuspid regurgitant jet velocityâ. American Journal of HematologyNA-NA
CrossRef95
Martin H. Steinberg, Willian F. McCarthy, Oswaldo Castro, Samir K. Ballas, F. Danny Armstrong, Wally Smith, Kenneth Ataga, Paul Swerdlow, Abdullah Kutlar, Laura DeCastro, Myron A. Waclawiw, . (2010) The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. American Journal of HematologyNA-NA
CrossRef96
Shahla G. Naoman, Mehdi Nouraie, Oswaldo L. Castro, Catherine Nwokolo, Margaret Fadojutimi-Akinsiku, Sharmin Diaz, Georgia Willie-Carnegie, Newton Andrews, Victor R. Gordeuk. (2010) Echocardiographic findings in patients with sickle cell disease. Annals of Hematology 89:1, 61-66
CrossRef97
Carlo Brugnara. (2010) ASH 2009 meeting report-Top 10 clinically oriented abstracts in sickle cell disease. American Journal of HematologyNA-NA
CrossRef98
Hsieh, Matthew M., Kang, Elizabeth M., Fitzhugh, Courtney D., Link, M. Beth, Bolan, Charles D., Kurlander, Roger, Childs, Richard W., Rodgers, Griffin P., Powell, Jonathan D., Tisdale, John F., . (2009) Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease. New England Journal of Medicine 361:24, 2309-2317
Full Text99
Caterina P. Minniti, Roberto F. Machado, Wynona A. Coles, Vandana Sachdev, Mark T. Gladwin, Gregory J. Kato. (2009) Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. British Journal of Haematology 147:5, 737-743
CrossRef100
Nazzareno Galiè, Marius M. Hoeper, Marc Humbert, Adam Torbicki, Jean-Luc Vachiery, Joan Albert Barberá, Maurice Beghetti, Paul Corris, Sean Gaine, J. Simon Gibbs, Miguel Ángel Gómez-Sánchez, Guillaume Jondeau, Walter Klepetko, Christian Opitz, Andrew Peacock, Lewis Rubin, Michael Zellweger, Gerald Simonneau. (2009) Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. Revista Española de Cardiología 62:12, 1464.e1-1464.e58
CrossRef101
V. R. Gordeuk, A. Campbell, S. Rana, M. Nouraie, X. Niu, C. P. Minniti, C. Sable, D. Darbari, N. Dham, O. Onyekwere, T. Ammosova, S. Nekhai, G. J. Kato, M. T. Gladwin, O. L. Castro. (2009) Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease. Blood 114:21, 4639-4644
CrossRef102
Mark T Gladwin, Daniel B Kim-Shapiro. (2009) Storage lesion in banked blood due to hemolysis-dependent disruption of nitric oxide homeostasis. Current Opinion in Hematology 16:6, 515-523
CrossRef103
, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, G. Simonneau, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, K. McGregor, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. Vardas, P. Widimsky, , U. Sechtem, N. Al Attar, F. Andreotti, M. Aschermann, R. Asteggiano, R. Benza, R. Berger, D. Bonnet, M. Delcroix, L. Howard, A. N. Kitsiou, I. Lang, A. Maggioni, J. E. Nielsen-Kudsk, M. Park, P. Perrone-Filardi, S. Price, M. T. S. Domenech, A. Vonk-Noordegraaf, J. L. Zamorano. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal 30:20, 2493-2537
CrossRef104
J. Thachil. (2009) The enigma of pulmonary hypertension after splenectomy--does the megakaryocyte provide a clue?. QJM 102:10, 743-745
CrossRef105
Robert I. Liem, Mary A. Nevin, Adrienne Prestridge, Luciana T. Young, Alexis A. Thompson. (2009) Functional capacity in children and young adults with sickle cell disease undergoing evaluation for cardiopulmonary disease. American Journal of Hematology 84:10, 645-649
CrossRef106
Joshua J. Field, Anusha R. Madadi, Marilyn J. Siegel, Vamsidhar Narra. (2009) Pulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated triscuspid regurgitant jet velocity. American Journal of Hematology 84:10, 686-688
CrossRef107
S. E. Crary, G. R. Buchanan. (2009) Vascular complications after splenectomy for hematologic disorders. Blood 114:14, 2861-2868
CrossRef108
Niti Dham, Gregory Ensing, Caterina Minniti, Andrew Campbell, Manuel Arteta, Sohail Rana, Deepika Darbari, Mehdi Nouraie, Onyinye Onyekwere, Malgorzata Lasota, Gregory J. Kato, Mark T. Gladwin, Oswaldo Castro, Victor Gordeuk, Craig Sable. (2009) Prospective Echocardiography Assessment of Pulmonary Hypertension and Its Potential Etiologies in Children With Sickle Cell Disease††Conflicts of interest: Dr. Gordeuk has received grants from BioMarin Pharmaceutical Inc., Novato, California, and Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, and is a consultant for Ikaria Holdings, Clinton, New Jersey.. The American Journal of Cardiology 104:5, 713-720
CrossRef109
Gregory J. Kato, Robert P. Hebbel, Martin H. Steinberg, Mark T. Gladwin. (2009) Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. American Journal of Hematology 84:9, 618-625
CrossRef110
Matthew Olnes, Amy Chi, Carissa Haney, Rose May, Caterina Minniti, James Taylor, Gregory J. Kato. (2009) Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. American Journal of Hematology 84:8, 529-531
CrossRef111
Margaret T. Lee, Tania Small, Muhammad A. Khan, Erika B. Rosenzweig, Robyn J. Barst, Gary M. Brittenham. (2009) Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years. British Journal of Haematology 146:4, 437-441
CrossRef112
Vassilios Tzortzis, Lampros Mitrakas, Stavros Gravas, Charalampos Mamoulakis, Andreas Meissner, Despina Kyriakou, Michael D. Melekos. (2009) Oral Phosphodiesterase Type 5 Inhibitors Alleviate Recurrent Priapism Complicating Thalassemia Intermedia: A Case Report. Journal of Sexual Medicine 6:7, 2068-2071
CrossRef113
Gérald Simonneau, Ivan M. Robbins, Maurice Beghetti, Richard N. Channick, Marion Delcroix, Christopher P. Denton, C. Gregory Elliott, Sean P. Gaine, Mark T. Gladwin, Zhi-Cheng Jing, Michael J. Krowka, David Langleben, Norifumi Nakanishi, Rogério Souza. (2009) Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology 54:1, S43-S54
CrossRef114
Athanasios Aessopos, Dimitrios Farmakis, Christos Trompoukis, Maria Tsironi, Ioannis Moyssakis, Panagiotis Tsaftarides, Markisia Karagiorga. (2009) Cardiac involvement in sickle β-thalassemia. Annals of Hematology 88:6, 557-564
CrossRef115
David B. Badesch, Hunter C. Champion, Miguel Angel Gomez Sanchez, Marius M. Hoeper, James E. Loyd, Alessandra Manes, Michael McGoon, Robert Naeije, Horst Olschewski, Ronald J. Oudiz, Adam Torbicki. (2009) Diagnosis and Assessment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 54:1, S55-S66
CrossRef116
Rachel Billy-Brissac, Anne Blanchet-Deverly, Maryse Etienne-Julan, Lydia Foucan. (2009) Pulmonary hypertension in an adult sickle cell population in Guadeloupe. International Journal of Cardiology 135:1, 122-123
CrossRef117
Ardie Pack-Mabien, Johnson Haynes. (2009) A primary care provider’s guide to preventive and acute care management of adults and children with sickle cell disease. Journal of the American Academy of Nurse Practitioners 21:5, 250-257
CrossRef118
Jocelyn Inamo, Philippe Connes, Jean-Claude Barthélémy, Viorel Dan, Thomas Coates, Gylna Loko. (2009) Pulmonary hypertension does not affect the autonomic nervous system dysfunction of sickle cell disease. American Journal of Hematology 84:5, 311-312
CrossRef119
Gregory J. Kato, Zeneng Wang, Roberto F. Machado, William C. Blackwelder, James G. Taylor th, Stanley L. Hazen. (2009) Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. British Journal of Haematology 145:4, 506-513
CrossRef120
Claudia R. Morris. (2009) Asthma management: Reinventing the wheel in sickle cell disease. American Journal of Hematology 84:4, 234-241
CrossRef121
Vallerie V. McLaughlin, Stephen L. Archer, David B. Badesch, Robyn J. Barst, Harrison W. Farber, Jonathan R. Lindner, Michael A. Mathier, Michael D. McGoon, Myung H. Park, Robert S. Rosenson, Lewis J. Rubin, Victor F. Tapson, John Varga. (2009) ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology 53:17, 1573-1619
CrossRef122
Farzana D. Pashankar, Judith Carbonella, Alia Bazzy-Asaad, Alan Friedman. (2009) Longitudinal follow up of elevated pulmonary artery pressures in children with sickle cell disease. British Journal of Haematology 144:5, 736-741
CrossRef123
Robert I. Liem, Mary A. Nevin, Adrienne Prestridge, Luciana T. Young, Alexis A. Thompson. (2009) Tricuspid regurgitant jet velocity elevation and its relationship to lung function in pediatric sickle cell disease. Pediatric Pulmonology 44:3, 281-289
CrossRef124
Gautam V. Ramani, Kathy Edelman, Angel López-Candales. (2009) Standard measures of right ventricular function assessment in adult patients with acute sickle cell crises. International Journal of Cardiology 132:3, 448-450
CrossRef125
Ian M. Balfour-Lynn. (2009) Domiciliary Oxygen for Children. Pediatric Clinics of North America 56:1, 275-296
CrossRef126
Aziza Sedrak, Sreedhar P. Rao, Scott T. Miller, Vahid Hekmat, Madu Rao. (2009) A Prospective Appraisal of Pulmonary Hypertension in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 31:2, 97-100
CrossRef127
Samir K. Ballas, Susan Lieff, Lennette J. Benjamin, Carlton D. Dampier, Matthew M. Heeney, Carolyn Hoppe, Cage S. Johnson, Zora R. Rogers, Kim Smith-Whitley, Winfred C. Wang, Marilyn J. Telen, . (2009) Definitions of the phenotypic manifestations of sickle cell disease. American Journal of HematologyNA-NA
CrossRef128
J. J. Field, M. R. DeBaun. (2009) Asthma and sickle cell disease: two distinct diseases or part of the same process?. Hematology 2009:1, 45-53
CrossRef129
Erika B. Rosenzweig, Robyn J. Barst. (2009) Pulmonary arterial hypertension in children: A Medical Update. The Indian Journal of Pediatrics 76:1, 77-81
CrossRef130
Winfred C Wang. (2008) The pharmacotherapy of sickle cell disease. Expert Opinion on Pharmacotherapy 9:17, 3069-3082
CrossRef131
Gladwin, Mark T., Vichinsky, Elliott, . (2008) Pulmonary Complications of Sickle Cell Disease. New England Journal of Medicine 359:21, 2254-2265
Full Text132
A. N. Schechter. (2008) Hemoglobin research and the origins of molecular medicine. Blood 112:10, 3927-3938
CrossRef133
Eduard J. van Beers, Erfan Nur, Cornelia M. Schaefer-Prokop, Melvin R. Mac Gillavry, Joost W.J. van Esser, Dees P.M. Brandjes, Maria C. Kappers-Klunne, Ashley J. Duits, Frits A.J. Muskiet, John-John B. Schnog, Bart J. Biemond, . (2008) Cardiopulmonary imaging, functional and laboratory studies in sickle cell disease associated pulmonary hypertension. American Journal of Hematology 83:11, 850-854
CrossRef134
Naim Issa, Michael J. Krowka, Matthew D. Griffin, LaTonya J. Hickson, Mark D. Stegall, Fernando G. Cosio. (2008) Pulmonary Hypertension Is Associated With Reduced Patient Survival After Kidney Transplantation. Transplantation 86:10, 1384-1388
CrossRef135
E. Hachulla, P. Carpentier, V. Gressin, E. Diot, Y. Allanore, J. Sibilia, D. Launay, L. Mouthon, P. Jego, J. Cabane, P. de Groote, A. Chabrol, I. Lazareth, L. Guillevin, P. Clerson, M. Humbert, . (2008) Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology 48:3, 304-308
CrossRef136
Priscilla Y Hsue, Jeffrey N Martin. (2008) Pulmonary arterial hypertension and HIV infection: authorsʼ reply. AIDS 22:16, 2220
CrossRef137
S. Yuditskaya, A. Tumblin, G. T. Hoehn, G. Wang, S. K. Drake, X. Xu, S. Ying, A. H. Chi, A. T. Remaley, R.-F. Shen, P. J. Munson, A. F. Suffredini, G. J. Kato. (2008) Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood 113:5, 1122-1128
CrossRef138
N. Patel, C. S. Gonsalves, M. Yang, P. Malik, V. K. Kalra. (2008) Placenta growth factor induces 5-lipoxygenase-activating protein to increase leukotriene formation in sickle cell disease. Blood 113:5, 1129-1138
CrossRef139
Aaron Schein, Cathleen Enriquez, Thomas D. Coates, John C. Wood. (2008) Magnetic resonance detection of kidney iron deposition in sickle cell disease: A marker of chronic hemolysis. Journal of Magnetic Resonance Imaging 28:3, 698-704
CrossRef140
A. Kyle Mack, Vicki R. McGowan II, Carole K. Tremonti, Diana Ackah, Christopher Barnett, Roberto F. Machado, Mark T. Gladwin, Gregory J. Kato. (2008) Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study. British Journal of Haematology 142:6, 971-978
CrossRef141
Raymond L. Benza. (2008) Pulmonary Hypertension Associated with Sickle Cell Disease: Pathophysiology and Rationale for Treatment. Lung 186:4, 247-254
CrossRef142
N. Patel, C. S. Gonsalves, P. Malik, V. K. Kalra. (2008) Placenta growth factor augments endothelin-1 and endothelin-B receptor expression via hypoxia-inducible factor-1 . Blood 112:3, 856-865
CrossRef143
Joshua J. Field, Paul F. Austin, Ping An, Yan Yan, Michael R. DeBaun. (2008) Enuresis Is a Common and Persistent Problem Among Children and Young Adults with Sickle Cell Anemia. Urology 72:1, 81-84
CrossRef144
Elizabeth S. Klings, Demedrick Anton Bland, Dara Rosenman, Stephanie Princeton, Adam Odhiambo, Guihua Li, Sheilah A. Bernard, Martin H. Steinberg, Harrison W. Farber. (2008) Pulmonary arterial hypertension and left‐sided heart disease in sickle cell disease: Clinical characteristics and association with soluble adhesion molecule expression. American Journal of Hematology 83:7, 547-553
CrossRef145
Precious P. Landburg, Tom Teerlink, Frits A.J. Muskiet, Ashley J. Duits, John‐John B. Schnog, . (2008) Plasma concentrations of asymmetric dimethylarginine, an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell patients but do not increase further during painful crisis. American Journal of Hematology 83:7, 577-579
CrossRef146
Lorenz H. Lehmann, Hanno Riess, Isrid Sturm. (2008) Sickle cell disease, pulmonary hypertension, and sarcoidosis. Annals of Hematology 87:7, 591-592
CrossRef147
M. H. Steinberg. (2008) SNPing away at sickle cell pathophysiology. Blood 111:12, 5420-5421
CrossRef148
A. E. Ashley-Koch, L. Elliott, M. E. Kail, L. M. De Castro, J. Jonassaint, T. L. Jackson, J. Price, K. I. Ataga, M. C. Levesque, J. B. Weinberg, E. P. Orringer, A. Collins, J. M. Vance, M. J. Telen. (2008) Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 111:12, 5721-5726
CrossRef149
Karrie Villavicencio, Dunbar Ivy, Laura Cole, Rachelle Nuss. (2008) Symptomatic Pulmonary Hypertension in a Child with Sickle Cell Disease. The Journal of Pediatrics 152:6, 879-881
CrossRef150
Jason B Caboot, Julian L Allen. (2008) Pulmonary complications of sickle cell disease in children. Current Opinion in Pediatrics 20:3, 279-287
CrossRef151
Zakari Y. Aliyu, Victor Gordeuk, Vandana Sachdev, Aliyu Babadoko, Aisha I. Mamman, Peter Akpanpe, Ester Attah, Yusuf Suleiman, Nurudeen Aliyu, Jamilu Yusuf, Laurel Mendelsohn, Gregory J. Kato, Mark T. Gladwin. (2008) Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. American Journal of Hematology 83:6, 485-490
CrossRef152
Erika B Rosenzweig, Robyn J Barst. (2008) Pulmonary arterial hypertension in children: a medical update. Current Opinion in Pediatrics 20:3, 288-293
CrossRef153
Swee Lay Thein. (2008) Genetic modifiers of the β-haemoglobinopathies. British Journal of Haematology 141:3, 357-366
CrossRef154
Priscilla Y Hsue, Steven G Deeks, Husam H Farah, Swapna Palav, Samira Y Ahmed, Amanda Schnell, Allison B Ellman, Laurence Huang, Sheila C Dollard, Jeffrey N Martin. (2008) Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS 22:7, 825-833
CrossRef155
Xiaojun He, Ivan Azarov, Anne Jeffers, Tennille Presley, Jodi Richardson, S. Bruce King, Mark T. Gladwin, Daniel B. Kim-Shapiro. (2008) The potential of Angeli's salt to decrease nitric oxide scavenging by plasma hemoglobin. Free Radical Biology and Medicine 44:7, 1420-1432
CrossRef156
Katherine C. Wood, Lewis L. Hsu, Mark T. Gladwin. (2008) Sickle cell disease vasculopathy: A state of nitric oxide resistance. Free Radical Biology and Medicine 44:8, 1506-1528
CrossRef157
Matthew M. Heeney, Russell E. Ware. (2008) Hydroxyurea for Children with Sickle Cell Disease. Pediatric Clinics of North America 55:2, 483-501
CrossRef158
Platt, Orah S., . (2008) Hydroxyurea for the Treatment of Sickle Cell Anemia. New England Journal of Medicine 358:13, 1362-1369
Full Text159
Ward Hagar, Elliott Vichinsky. (2008) Advances in clinical research in sickle cell disease. British Journal of Haematology 0:0, 080313115903451-???
CrossRef160
O. C. Onyekwere, A. Campbell, M. Teshome, S. Onyeagoro, C. Sylvan, A. Akintilo, S. Hutchinson, G. Ensing, P. Gaskin, G. Kato, S. Rana, J. Kwagyan, V. Gordeuk, J. Williams, O. Castro. (2008) Pulmonary Hypertension in Children and Adolescents with Sickle Cell Disease. Pediatric Cardiology 29:2, 309-312
CrossRef161
K. I. Ataga, W. R. Smith, L. M. De Castro, P. Swerdlow, Y. Saunthararajah, O. Castro, E. Vichinsky, A. Kutlar, E. P. Orringer, G. C. Rigdon, J. W. Stocker, . (2008) Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 111:8, 3991-3997
CrossRef162
Laura S. Inselman. 2008. Pulmonary Manifestations of Systemic Disorders. , 1053-1079.
CrossRef163
Steven H. Abman. 2008. Cor Pulmonale and Pulmonary Complications of Cardiac Disease. , 735-757.
CrossRef164
G. J. Kato. (2008) Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I. Hematology 2008:1, 186-192
CrossRef165
Stephen Y. Chan, Joseph Loscalzo. (2008) Pathogenic mechanisms of pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology 44:1, 14-30
CrossRef166
Laura M. De Castro, Jude C. Jonassaint, Felicia L. Graham, Allison Ashley-Koch, Marilyn J. Telen. (2008) Pulmonary hypertension associated with sickle cell disease: Clinical and laboratory endpoints and disease outcomes. American Journal of Hematology 83:1, 19-25
CrossRef167
Zakari Y. Aliyu, Gregory J. Kato, James Taylor, Aliyu Babadoko, Aisha I. Mamman, Victor R. Gordeuk, Mark T. Gladwin. (2008) Sickle cell disease and pulmonary hypertension in Africa: A global perspective and review of epidemiology, pathophysiology, and management. American Journal of Hematology 83:1, 63-70
CrossRef168
Kristin B. Highland. (2008) Pulmonary Arterial Hypertension. The American Journal of the Medical Sciences 335:1, 40-45
CrossRef169
Victor R. Gordeuk, Vandana Sachdev, James G. Taylor, Mark T. Gladwin, Gregory Kato, Oswaldo L. Castro. (2008) Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. American Journal of Hematology 83:1, 15-18
CrossRef170
Elizabeth S. Klings. (2008) Pulmonary hypertension of sickle cell disease: More than just another lung disease. American Journal of Hematology 83:1, 4-5
CrossRef171
Lakshmanan Krishnamurti, H. Franklin Bunn, Andrea M. Williams, Jakub Tolar. (2008) Hematopoietic Cell Transplantation for Hemoglobinopathies. Current Problems in Pediatric and Adolescent Health Care 38:1, 6-18
CrossRef172
Tae W Kim. (2008) Perioperative Care of the Patient With Sickle Cell Disease. ASA Refresher Courses in Anesthesiology 36:1, 61-74
CrossRef173
James G. Taylor, Diana Ackah, Crystal Cobb, Nick Orr, Melanie J. Percy, Vandana Sachdev, Roberto Machado, Oswaldo Castro, Gregory J. Kato, Stephen J. Chanock, Mark T. Gladwin. (2008) Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. American Journal of Hematology 83:1, 6-14
CrossRef174
Martin H. Steinberg. (2008) Clinical trials in sickle cell disease: Adopting the combination chemotherapy paradigm. American Journal of Hematology 83:1, 1-3
CrossRef175
Lakshmanan Krishnamurti, Lizabeth Lanford, Ricardo Munoz. (2007) Life threatening parvovirus B19 and herpes simplex virus associated acute myocardial dysfunction in a child with homozygous sickle cell disease. Pediatric Blood & Cancer 49:7, 1019-1021
CrossRef176
Mitchell E. Horwitz, Ivan Spasojevic, Ashley Morris, Marilyn Telen, James Essell, Cristina Gasparetto, Keith Sullivan, Gwynn Long, John Chute, Nelson Chao, David Rizzieri. (2007) Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. Biology of Blood and Marrow Transplantation 13:12, 1422-1426
CrossRef177
Sandra O’Driscoll, Susan E. Height, Moira C. Dick, David C. Rees. (2007) Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. British Journal of Haematology 0:0, 071119224223004-???
CrossRef178
S Shenoy. (2007) Has stem cell transplantation come of age in the treatment of sickle cell disease?. Bone Marrow Transplantation 40:9, 813-821
CrossRef179
R. Ward Hagar, Jennifer G. Michlitsch, Jennifer Gardner, Elliott P. Vichinsky, Claudia R. Morris. (2007) Clinical differences between children and adults with pulmonary hypertension and sickle cell disease. British Journal of Haematology 0:0, 071003043944004-???
CrossRef180
Kenneth I. Ataga, Maria D. Cappellini, Eliezer A. Rachmilewitz. (2007) ?-Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. British Journal of Haematology 139:1, 3-13
CrossRef181
J. Villagra, S. Shiva, L. A. Hunter, R. F. Machado, M. T. Gladwin, G. J. Kato. (2007) Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 110:6, 2166-2172
CrossRef182
Mark C. Walters. (2007) Cord blood transplantation for sickle cell anemia: Bust or boom?. Pediatric Transplantation 11:6, 582-583
CrossRef183
Adam Odhiambo, David H. Perlman, Hua Huang, Catherine E. Costello, Harrison W. Farber, Martin H. Steinberg, Mark E. McComb, Elizabeth S. Klings. (2007) Identification of oxidative post-translational modification of serum albumin in patients with idiopathic pulmonary arterial hypertension and pulmonary hypertension of sickle cell anemia. Rapid Communications in Mass Spectrometry 21:14, 2195-2203
CrossRef184
Vandana Sachdev, Roberto F. Machado, William C. Blackwelder, Gregory J. Kato, Mark T. Gladwin. (2007) Reply. Journal of the American College of Cardiology 50:4, 378-379
CrossRef185
Dominik J. Schaer, Abdu I. Alayash, Paul W. Buehler. (2007) Gating the Radical Hemoglobin to Macrophages: The Anti-Inflammatory Role of CD163, a Scavenger Receptor. Antioxidants & Redox Signaling 9:7, 991-999
CrossRef186
Julie A. Panepinto, Mark C. Walters, Jeanette Carreras, Judith Marsh, Christopher N. Bredeson, Robert Peter Gale, Gregory A. Hale, John Horan, Jill M. Hows, John P. Klein, Ricardo Pasquini, Irene Roberts, Keith Sullivan, Mary Eapen, Alina Ferster, . (2007) Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. British Journal of Haematology 137:5, 479-485
CrossRef187
David C. Brousseau, D. Gail McCarver, Amy L. Drendel, Karthika Divakaran, Julie A. Panepinto. (2007) The Effect of CYP2D6 Polymorphisms on the Response to Pain Treatment for Pediatric Sickle Cell Pain Crisis. The Journal of Pediatrics 150:6, 623-626
CrossRef188
J.G. Coghlan, C.E. Handler, P.D. Kottaridis. (2007) Cardiac assessment of patients for haematopoietic stem cell transplantation. Best Practice & Research Clinical Haematology 20:2, 247-263
CrossRef189
W. Craig Hooper, George A. Mensah, S.G. Haworth, Stephen M. Black, Joe G.N. Garcia, David Langleben. (2007) Vascular endothelium summary statement V: Pulmonary hypertension and acute lung injury: Public health implications. Vascular Pharmacology 46:5, 327-329
CrossRef190
Stephen C. Nelson, Beverly B. Adade, Elizabeth A. McDonough, Kristin L. Moquist, Jane M. Hennessy. (2007) High Prevalence of Pulmonary Hypertension in Children With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 29:5, 334-337
CrossRef191
Athanassios Aessopos, Maria Kati, John Meletis. (2007) Thalassemia intermedia today: should patients regularly receive transfusions?. Transfusion 47:5, 792-800
CrossRef192
Anita Hill, Stephen J. Richards, Peter Hillmen. (2007) Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria. British Journal of Haematology 137:3, 181-192
CrossRef193
Cassandra D. Josephson, Leon L. Su, Krista L. Hillyer, Christopher D. Hillyer. (2007) Transfusion in the Patient With Sickle Cell Disease: A Critical Review of the Literature and Transfusion Guidelines. Transfusion Medicine Reviews 21:2, 118-133
CrossRef194
Athanasios Aessopos, Dimitrios Farmakis, Maria Tsironi, Evanthia Diamanti-Kandarakis, Marina Matzourani, Christina Fragodimiri, Antonia Hatziliami, Markisia Karagiorga. (2007) Endothelial function and arterial stiffness in sickle-thalassemia patients. Atherosclerosis 191:2, 427-432
CrossRef195
Tami D. Benton, Judith A. Ifeagwu, Kim Smith-Whitley. (2007) Anxiety and depression in children and adolescents with sickle cell disease. Current Psychiatry Reports 9:2, 114-121
CrossRef196
Peter H. Michelson, Rakesh Goyal, Geoffrey Kurland. (2007) Pulmonary complications of haematopoietic cell transplantation in children. Paediatric Respiratory Reviews 8:1, 46-61
CrossRef197
Terence K. Trow, John R. McArdle. (2007) Diagnosis of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 59-73
CrossRef198
Holger N. Lode, Gregor Krings, Ingram Schulze-Neick, Steffen D??hmlow, Ulrike Schroeder, Ragnhild Bonnet, Joao DaPalma, Werner Luck, Gabriele Strau, Felix Berger, Gerhard Gaedicke. (2007) Pulmonary Hypertension in a Case of Hb-Mainz Hemolytic Anemia. Journal of Pediatric Hematology/Oncology 29:3, 173-177
CrossRef199
Darren B. Taichman, Jess Mandel. (2007) Epidemiology of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 1-22
CrossRef200
Lakshmanan Krishnamurti. (2007) Hematopoietic cell transplantation for sickle cell disease: state of the art. Expert Opinion on Biological Therapy 7:2, 161-172
CrossRef201
Claudia R Morris, Sylvia T Singer, Mark C Walters. (2007) Clinical hemoglobinopathies: iron, lungs and new blood. Current Opinion in Internal Medicine 6:1, 60-71
CrossRef202
Roberto F. Machado, A. Kyle Mack, Sabrina Martyr, Christopher Barnett, Peter MacArthur, Vandana Sachdev, Inez Ernst, Lori A. Hunter, Wynona A. Coles, James P. Nichols, Gregory J. Kato, Mark T. Gladwin. (2007) Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. British Journal of Haematology 136:2, 319-325
CrossRef203
Ferit Akgül, Ergün Seyfeli, İsmet Melek, Taşkin Duman, Tunzale Seydaliyeva, Edip Gali, Fatih Yalçın. (2007) Increased QT Dispersion in Sickle Cell Disease: Effect of Pulmonary Hypertension. Acta Haematologica 118:1, 1-6
CrossRef204
Yun Zhang, Yungang Qui, Jianhua Zhu, Danchen Gao. (2007) Pulmonary hypertension associated with autoimmune hemolytic anemia: A case report. International Journal of Cardiology 115:1, E1-E2
CrossRef205
Bryan Ristow, Sadia Ali, Xiushui Ren, Mary A. Whooley, Nelson B. Schiller. (2007) Elevated Pulmonary Artery Pressure by Doppler Echocardiography Predicts Hospitalization for Heart Failure and Mortality in Ambulatory Stable Coronary Artery Disease. Journal of the American College of Cardiology 49:1, 43-49
CrossRef206
Vandana Sachdev, Roberto F. Machado, Yukitaka Shizukuda, Yesoda N. Rao, Stanislav Sidenko, Inez Ernst, Marilyn St. Peter, Wynona A. Coles, Douglas R. Rosing, William C. Blackwelder, Oswaldo Castro, Gregory J. Kato, Mark T. Gladwin. (2007) Diastolic Dysfunction Is an Independent Risk Factor for Death in Patients With Sickle Cell Disease. Journal of the American College of Cardiology 49:4, 472-479
CrossRef207
Kenneth Ataga, Richard Lottenberg. 2007. Hemostatic Aspects of Sickle Cell Disease. , 723-735.
CrossRef208
Christopher F Barnett, Roberto F Machado. (2006) Sildenafil in the treatment of pulmonary hypertension. Vascular Health and Risk Management 2:4, 411-422
CrossRef209
Steven J. Ambrusko, Sriya Gunawardena, Allison Sakara, Beth Windsor, Lizabeth Lanford, Peter Michelson, Lakshmanan Krishnamurti. (2006) Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatric Blood & Cancer 47:7, 907-913
CrossRef210
Deepika S. Darbari, Paul Kple-Faget, John Kwagyan, Sohail Rana, Victor R. Gordeuk, Oswaldo Castro. (2006) Circumstances of death in adult sickle cell disease patients. American Journal of Hematology 81:11, 858-863
CrossRef211
R. Dickerhoff. (2006) Sichelzellkrankheit in Deutschland. Monatsschrift Kinderheilkunde 154:11, 1081-1089
CrossRef212
Anne Jeffers, Mark T. Gladwin, Daniel B. Kim-Shapiro. (2006) Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radical Biology and Medicine 41:10, 1557-1565
CrossRef213
Sylvia T. Singer, Frans A. Kuypers, Lori Styles, Elliott P. Vichinsky, Drucella Foote, Howard Rosenfeld. (2006) Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable state. American Journal of Hematology 81:9, 670-675
CrossRef214
Ferit Akgül, Fatih Yalçin, Cenk Babayiğit, Ergün Seyfeli, Tunzale Seydaliyeva, Edip Gali. (2006) Right Ventricular and Pulmonary Function in Sickle Cell Disease Patients with Pulmonary Hypertension. Pediatric Cardiology 27:4, 440-446
CrossRef215
Vincent Audard, Philippe Grimbert, Matthias Kirsch, M. Anoosha Habibi, Philippe Lang, Philippe Remy, Claude Abbou, Daniel Loisance, Nicole Benaiem, Dora Bachir, Emmanuelle Vermes. (2006) Successful Combined Heart and Kidney Transplantation in a Patient With Sickle-cell Anemia. The Journal of Heart and Lung Transplantation 25:8, 993-996
CrossRef216
Seiji Hayashi, Hiroto Matsuoka, Teruo Harano, Keiko Harano, Hiroshi Nakahara, Isao Tachibana, Hiroshi Kida, Tomio Kawasaki, Shingo Kyotani, Yoshihiro Oka, Mitsunori Sakatani, Ichiro Kawase. (2006) A Case of Alpha-Thalassemia-2 Associated with Pulmonary Infarction. Lung 184:4, 223-227
CrossRef217
Gregory J. Kato, Matthew Hsieh, Roberto Machado, James Taylor, Jane Little, John A. Butman, Tanya Lehky, John Tisdale, Mark T. Gladwin. (2006) Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology 81:7, 503-510
CrossRef218
Kenneth I. Ataga, Charity G. Moore, Susan Jones, Oludamilola Olajide, Dell Strayhorn, Alan Hinderliter, Eugene P. Orringer. (2006) Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. British Journal of Haematology 134:1, 109-115
CrossRef219
Zaid Abassi, Farid Nakhoul, Eliyahu Khankin, Shimon A Reisner, Mordechai Yigla. (2006) Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Current Opinion in Nephrology and Hypertension 15:4, 353-360
CrossRef220
Jan Balzer, Christian Heiss, Hagen Schroeter, Paris Brouzos, Petra Kleinbongard, Simone Matern, Thomas Lauer, Tienush Rassaf, Malte Kelm. (2006) Flavanols and Cardiovascular Health: Effects on the circulating NO Pool in Humans. Journal of Cardiovascular Pharmacology 47:Supplement 2, S122-S127
CrossRef221
Vikki G. Nolan, Adeboye Adewoye, Clinton Baldwin, Ling Wang, Qianli Ma, Diego F. Wyszynski, John J. Farrell, Paola Sebastiani, Lindsay A. Farrer, Martin H. Steinberg. (2006) Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. British Journal of Haematology 133:5, 570-578
CrossRef222
Denise H. Tam, Harrison W. Farber. (2006) Pulmonary hypertension and β-thalassemia major: Report of a case, its treatment, and a review of the literature. American Journal of Hematology 81:6, 443-447
CrossRef223
Nathalie Dauphin-McKenzie, Jerry M. Gilles, Elvire Jacques, Thomas Harrington. (2006) Sickle Cell Anemia in the Female Patient. Obstetrical & Gynecological Survey 61:5, 343-352
CrossRef224
R. W. Hagar, C. R. Morris, E. P. Vichinsky. (2006) Pulmonary hypertension in thalassaemia major patients with normal left ventricular systolic function. British Journal of Haematology 133:4, 433-435
CrossRef225
Alexis A. Thompson. (2006) Advances in the management of sickle cell disease. Pediatric Blood & Cancer 46:5, 533-539
CrossRef226
Martin H Steinberg, Adeboye H Adewoye. (2006) Modifier genes and sickle cell anemia. Current Opinion in Hematology 13:3, 131-136
CrossRef227
Anna R Hemnes, Hunter C Champion. (2006) Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Expert Review of Cardiovascular Therapy 4:3, 293-300
CrossRef228
Brian Laurence, David George, Dexter Woods, Adeyemisi Shosanya, Ralph V. Katz, Sophie Lanzkron, Marie Diener-West, Neil Powe. (2006) The association between sickle cell disease and dental caries in African Americans. Special Care in Dentistry 26:3, 95-100
CrossRef229
Martin H. Steinberg. (2006) Pathophysiologically based drug treatment of sickle cell disease. Trends in Pharmacological Sciences 27:4, 204-210
CrossRef230
Patricia A. Thistlethwaite, Aaron Kemp, Lingling Du, Michael M. Madani, Stuart W. Jamieson. (2006) Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. The Journal of Thoracic and Cardiovascular Surgery 131:2, 307-313
CrossRef231
Roberto F. Machado, Mark T. Gladwin. 2006. Hemolytic Anemia Associated Pulmonary Hypertension. , 170-187.
CrossRef232
Claudia R Morris. (2006) New Strategies for the Treatment of Pulmonary Hypertension in Sickle Cell Disease. Treatments in Respiratory Medicine 5:1, 31-45
CrossRef233
A. Kyle Mack, Gregory J. Kato. (2006) Sickle cell disease and nitric oxide: A paradigm shift?. The International Journal of Biochemistry & Cell Biology 38:8, 1237-1243
CrossRef234
Samir K. Ballas, Mary Jane Marcolina. (2006) Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion 46:1, 105-110
CrossRef235
Lakshmanan Krishnamurti. (2006) Commentary on ???Identification of Unrelated Cord Blood Units for Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease???. Journal of Pediatric Hematology/Oncology 28:1, 1-3
CrossRef236
A. El-Beshlawy, E. Abd El Raouf, F. Mostafa, M. Talaat, H. Isma’eel, E. Aoun, A.V. Hoffbrand, A. Taher. (2006) Diastolic Dysfunction and Pulmonary Hypertension in Sickle Cell Anemia: Is There a Role for <i>L</i>-Carnitine Treatment?. Acta Haematologica 115:1-2, 91-96
CrossRef237
Ashok B. Raj, Tania Condurache, Salvatore Bertolone, David Williams, Douglas Lorenz, Walter Sobczyk. (2005) Quantitative assessment of ventricular function in sickle cell disease: Effect of long-term erythrocytapheresis. Pediatric Blood & Cancer 45:7, 976-981
CrossRef238
Mary Nell Suell, Louis I Bezold, M Fatih Okcu, Donald H Mahoney, Felix Shardonofsky, Brigitta U Mueller. (2005) Increased Pulmonary Artery Pressures Among Adolescents With Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 27:12, 654-658
CrossRef239
ATHANASIOS AESSOPOS, DIMITRIOS FARMAKIS. (2005) Pulmonary Hypertension in β-Thalassemia. Annals of the New York Academy of Sciences 1054:1, 342-349
CrossRef240
GIORGIO DERCHI, GIAN LUCA FORNI. (2005) Therapeutic Approaches to Pulmonary Hypertension in Hemoglobinopathies: Efficacy and Safety of Sildenafil in the Treatment of Severe Pulmonary Hypertension in Patients with Hemoglobinopathy. Annals of the New York Academy of Sciences 1054:1, 471-475
CrossRef241
CLAUDIA R. MORRIS, FRANS A. KUYPERS, GREGORY J. KATO, LISA LAVRISHA, SANDRA LARKIN, TITI SINGER, ELLIOTT P. VICHINSKY. (2005) Hemolysis-Associated Pulmonary Hypertension in Thalassemia. Annals of the New York Academy of Sciences 1054:1, 481-485
CrossRef242
M.D CAPPELLINI, E. GRESPI, E. CASSINERIO, D. BIGNAMINI, G. FIORELLI. (2005) Coagulation and Splenectomy: An Overview. Annals of the New York Academy of Sciences 1054:1, 317-324
CrossRef243
Darleen R. Powars, Linda S. Chan, Alan Hiti, Emily Ramicone, Cage Johnson. (2005) Outcome of Sickle Cell Anemia. Medicine 84:6, 363-376
CrossRef244
Iris D. Buchanan, Maribel Woodward, George W. Reed. (2005) Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome. Pediatric Blood & Cancer 45:5, 716-724
CrossRef245
Cage S. Johnson. (2005) The Acute Chest Syndrome. Hematology/Oncology Clinics of North America 19:5, 857-879
CrossRef246
Akihiro Yoshimoto, Masaki Fujimura, Shinji Nakao. (2005) Pulmonary Hypertension after Splenectomy in Hereditary Stomatocytosis. The American Journal of the Medical Sciences 330:4, 195-197
CrossRef247
Charles T. Quinn, Naveed Ahmad. (2005) Clinical correlates of steady-state oxyhaemoglobin desaturation in children who have sickle cell disease. British Journal of Haematology 131:1, 129-134
CrossRef248
Sam O. Wanko, Marilyn J. Telen. (2005) Transfusion Management in Sickle Cell Disease. Hematology/Oncology Clinics of North America 19:5, 803-826
CrossRef249
Oswaldo Castro, Mark T. Gladwin. (2005) Pulmonary Hypertension in Sickle Cell Disease: Mechanisms, Diagnosis, and Management. Hematology/Oncology Clinics of North America 19:5, 881-896
CrossRef250
Gregory J. Kato, Sabrina Martyr, William C. Blackwelder, James S. Nichols, Wynona A. Coles, Lori A. Hunter, Marie-Luise Brennan, Stanley L. Hazen, Mark T. Gladwin. (2005) Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British Journal of Haematology 130:6, 943-953
CrossRef251
John P. Kinsella, Steven H. Abman. (2005) Inhaled nitric oxide therapy in children. Paediatric Respiratory Reviews 6:3, 190-198
CrossRef252
Adlah Sukkar, Daniel J. Mollura, Karen E. King, Jerry L. Spivak, Paul M. Hassoun, John F. McDyer. (2005) A Case of Pulmonary Hypertension Associated With a Rare Congenital Hemolytic Anemia. Clinical Pulmonary Medicine 12:5, 319-322
CrossRef253
Roberto F. Machado, Sabrina Martyr, Gregory J. Kato, Robyn J. Barst, Anastasia Anthi, Michael R. Robinson, Lori Hunter, Wynona Coles, James Nichols, Christian Hunter, Vandana Sachdev, Oswaldo Castro, Mark T. Gladwin. (2005) Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. British Journal of Haematology 130:3, 445-453
CrossRef254
F. Nakhoul. (2005) The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrology Dialysis Transplantation 20:8, 1686-1692
CrossRef255
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Medoff, Benjamin D., Shepard, Jo-Anne O., Smith, R. Neal, Kratz, Alexander, . (2005) Case 17-2005. New England Journal of Medicine 352:23, 2425-2434
Full Text256
Roberto F. Machado, Mark T. Gladwin. (2005) Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. British Journal of Haematology 129:4, 449-464
CrossRef257
M. H. Steinberg. (2005) Predicting clinical severity in sickle cell anaemia. British Journal of Haematology 129:4, 465-481
CrossRef258
J. B. Schnog, T. Teerlink, F. P. L. Dijs, A. J. Duits, F. A. J. Muskiet, . (2005) Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Annals of Hematology 84:5, 282-286
CrossRef259
(2005) Erratum. Journal of Thrombosis and Thrombolysis 19:2, 139-139
CrossRef260
Arnon Blum, Shay Yeganeh, Aviva Peleg, Fina Vigder, Konstantin Kryuger, Ahmed Khatib, Khalid Khazim, Harold Dauerman. (2005) Endothelial Function in Patients with Sickle Cell Anemia During and After Sickle Cell Crises. Journal of Thrombosis and Thrombolysis 19:2, 83-86
CrossRef261
Carolyn Hoppe. (2005) Defining stroke risk in children with sickle cell anaemia. British Journal of Haematology 128:6, 751-766
CrossRef262
Perla Vicari, Rita de Cassia Rosario Cavalheiro, Aparecida de Gouveia, Orlando Campos Filho, Maria Stella Figueiredo. (2005) Echocardiographic abnormalities in Brazilian sickle cell patients. American Journal of Hematology 78:2, 160-161
CrossRef263
Charles T. Quinn, Scott T. Miller. (2004) Risk factors and prediction of outcomes in children and adolescents who have sickle cell anemia. Hematology/Oncology Clinics of North America 18:6, 1339-1354
CrossRef264
Farber, Harrison W., Loscalzo, Joseph, . (2004) Pulmonary Arterial Hypertension. New England Journal of Medicine 351:16, 1655-1665
Full Text265
Marie J Stuart, Ronald L Nagel. (2004) Sickle-cell disease. The Lancet 364:9442, 1343-1360
CrossRef266
(2004) Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease. New England Journal of Medicine 350:24, 2521-2522
Full Text267
Vichinsky, Elliott P., . (2004) Pulmonary Hypertension in Sickle Cell Disease. New England Journal of Medicine 350:9, 857-859
Full Text
- Letters
